Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Linping Gu
ResearcherPublications, citations & collaboration network
Linping Gu is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 15 works, 212 citations, an h-index of 5 and an i10-index of 4.
15
Works
212
Citations
5
h-index
4
i10-index
IDs:OpenAlex
How has Linping Gu's publication output changed over time?
ScholarIQpublication output · 2010–2023
Output grew100% over the shown period — from 1 works in 2010 to 2 in 2023.
1
1
1
1
1
2
2
2
20102013201520192020202120222023
What are the most-cited papers on Linping Gu?
ScholarIQmost cited works
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Zhen Zhou, Zhengping Ding, Jie Yuan, Shengping Shen, Hong Jian, Qiang Tan, Yunhai Yang, Zhiwei Chen, Qingquan Luo, Xinghua Cheng, Yongfeng Yu, Xiaomin Niu, Liqiang Qian, Xiaoke Chen, Linping Gu, Ruijun Liu, Shenglin Ma, Jia Huang, Tianxiang Chen, Ziming Li, Wenxiang Ji, Liwei Song, Lan Shen, Long Jiang, Zicheng Yu, Chao Zhang, Zaixian Tai, Changxi Wang, Rongrong Chen, David P. Carbone, Xuefeng Xia, Shun Lu
S46507181. 202275 CitationsOPEN ACCESS
Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma
Linping Gu, Yunhua Xu, Zhiwei Chen, Yan Pan, Shun Lü
Biomedicine & Pharmacotherapy. 201560 Citations
Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors
Zhen Zhou, Yi Zhao, Shengping Shen, Linping Gu, Xiaomin Niu, Yunhua Xu, Téngfēi Zhāng, Jianxing Xiang, Xinru Mao, Shun Lü
Journal of Thoracic Oncology. 201939 CitationsOPEN ACCESS
No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis
Yunhua Xu, Linping Gu, Yingjia Sun, Bai-jun Cheng, Shun Lu
S12644804. 201312 Citations
An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu
Frontiers in Immunology. 20227 CitationsOPEN ACCESS
Related on ScholarIQ
Shanghai Jiao Tong University
Institution
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients
Paper
Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma
Paper
Durable Clinical Response of Lung Adenocarcinoma Harboring EGFR 19Del/T790M/in trans-C797S to Combination Therapy of First- and Third-Generation EGFR Tyrosine Kinase Inhibitors
Paper
No significant association between the XRCC3 Thr241Met polymorphism and lung cancer risk: a meta-analysis
Paper
An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis
Paper